AZD-0120
- Generic Name
- AZD-0120
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1
Recruiting
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06897930
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath